Skip to main content

Table 3 Recurrences and disease-free survival in 181 node-negative breast cancer patients after different adjuvant systemic therapies or no therapy

From: C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer

Subgroup   n Recurrence (n [%]) DFS (P)
Chemotherapy (n = 61)
   c-myc Amplified 19 3 (15.8) 0.1748
  Nonamplified 42 2 (4.8)  
HER-2/neu Amplified 26 1 (3.8) 0.2552
  Nonamplified 35 4 (11.4)  
Endocrine therapy (n= 99)
   c-myc Amplified 15 1 (6.7) 0.3325
  Nonamplified 84 2 (2.4)  
HER-2/neu Amplified 22 1 (4.5) 0.6641
  Nonamplified 77 2 (2.6)  
No therapy (n = 21)
   c-myc Amplified 5 1 (20.0) 0.0209*
  Nonamplified 16 0 (0)  
HER-2/neu Amplified 7 0 (0) 0.4969
  Nonamplified 14 1 (7.1)  
  1. *P < 0.05 (log-rank test). DFS, disease-free survival.